ArticleFrontiers in microbiology2025
Characterization of
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Role of Mobilome in Carbapenem Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- The flexible cotransfer of plasmids drives the dissemination of tet(X4) in swine Escherichia coli.Veterinary research · 2026Article
- Article
- Epidemiology, resistance profiles, and molecular characteristics of pediatric salmonella isolates: prevalence of a clonalFrontiers in cellular and infection microbiology · 2026Article
- Coexistence of aInfection and drug resistance · 2026Article
- ConfrontingInfection and drug resistance · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Methods: In this study, two clinical Results: Both isolates were multidrug resistant, with insusceptibility to ampicillin, ampicillin/sulbactam, amoxicillin/clavulanic acid, cefuroxime, ceftiofur, cefazolin, cefoxitin, cefotaxime, ceftazidime, cefepime, ceftazidime/avibactam, meropenem, imipenem, ertapenem, tetracycline, gentamicin, trimethoprim/sulfamethoxazole, florfenicol, chloramphenicol, ciprofloxacin, colistin, and polymixin B. The Discussion: This is the first report to describe the presence of two
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.